163 related articles for article (PubMed ID: 36307410)
1. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ; Ang WXG; Wang WW; Chong HS; Tan SH; Cheong R; Chia JW; Syn NL; Shuen WH; Ba R; Kaliaperumal N; Au B; Hopkins R; Li X; Tan AC; Seet AOL; Connolly JE; Arkachaisri T; Chew V; Lajam ABM; Guo D; Chew MZW; Wasser M; Kumar P; Albani S; Toh HC
Nat Commun; 2022 Oct; 13(1):6453. PubMed ID: 36307410
[TBL] [Abstract][Full Text] [Related]
2. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
Tang Y; Zhang L; Yuan J; Akbulut H; Maynard J; Linton PJ; Deisseroth A
Blood; 2004 Nov; 104(9):2704-13. PubMed ID: 15238426
[TBL] [Abstract][Full Text] [Related]
3. Addition of adenoviral vector targeting of chemotherapy to the MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs survival of mice carrying growing subcutaneous deposits of Lewis lung cancer cells.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Deisseroth A
Gene Ther; 2010 Nov; 17(11):1333-40. PubMed ID: 20596057
[TBL] [Abstract][Full Text] [Related]
4. Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
Akbulut H; Tang Y; Akbulut KG; Maynard J; Zhang L; Deisseroth A
Mol Cancer Ther; 2006 Aug; 5(8):1975-85. PubMed ID: 16928818
[TBL] [Abstract][Full Text] [Related]
5. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.
Zhang L; Tang Y; Akbulut H; Zelterman D; Linton PJ; Deisseroth AB
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15101-6. PubMed ID: 14645711
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Gatti-Mays ME; Redman JM; Donahue RN; Palena C; Madan RA; Karzai F; Bilusic M; Sater HA; Marté JL; Cordes LM; McMahon S; Steinberg SM; Orpia A; Burmeister A; Schlom J; Gulley JL; Strauss J
Oncologist; 2020 Jun; 25(6):479-e899. PubMed ID: 31594913
[TBL] [Abstract][Full Text] [Related]
9. TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and infectious diseases.
Deisseroth A; Tang Y; Zhang L; Akbulut H; Habib N
Cancer Gene Ther; 2013 Feb; 20(2):65-9. PubMed ID: 23238593
[TBL] [Abstract][Full Text] [Related]
10. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC.
van Leeuwen EB; Cloosen S; Senden-Gijsbers BL; Germeraad WT; Bos GM
Cytotherapy; 2006; 8(1):36-46. PubMed ID: 16627343
[TBL] [Abstract][Full Text] [Related]
11. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
13. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.
Castro JE; Melo-Cardenas J; Urquiza M; Barajas-Gamboa JS; Pakbaz RS; Kipps TJ
Cancer Res; 2012 Jun; 72(12):2937-48. PubMed ID: 22505652
[TBL] [Abstract][Full Text] [Related]
14. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.
Scholl SM; Balloul JM; Le Goc G; Bizouarne N; Schatz C; Kieny MP; von Mensdorff-Pouilly S; Vincent-Salomon A; Deneux L; Tartour E; Fridman W; Pouillart P; Acres B
J Immunother; 2000; 23(5):570-80. PubMed ID: 11001550
[TBL] [Abstract][Full Text] [Related]
15. Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens.
Sánchez Ramos O; González Pose A; Gómez-Puerta S; Noda Gomez J; Vega Redondo A; Águila Benites JC; Suárez Amarán L; Parra NC; Toledo Alonso JR
Comp Immunol Microbiol Infect Dis; 2011 May; 34(3):259-65. PubMed ID: 21190734
[TBL] [Abstract][Full Text] [Related]
16. CD40-ligand/interleukin-2 vaccines in chronic lymphocytic leukemia: the impact of vaccine design.
Rezvani K
Cytotherapy; 2011 Oct; 13(9):1029-30. PubMed ID: 21916777
[No Abstract] [Full Text] [Related]
17. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
18. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.
Okur FV; Yvon E; Biagi E; Dotti G; Carrum G; Heslop H; Mims MP; Fratantoni JC; Peshwa MV; Li L; Brenner MK
Cytotherapy; 2011 Oct; 13(9):1128-39. PubMed ID: 21745159
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Miles DW; Taylor-Papadimitriou J
Pharmacol Ther; 1999 Apr; 82(1):97-106. PubMed ID: 10341360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]